ストックスクリーナーアプリを入手
29.90
0.37%
-0.11
プレマーケット:
30.35
0.45
+1.51%
前日終値:
$30.01
開ける：
$30.08
24時間の取引高:
1.96M
Relative Volume:
1.15
時価総額：
$3.86B
収益：
-
当期純損益:
$-507.65M
株価収益率:
-6.50
EPS:
-4.6
ネットキャッシュフロー:
$-616.24M
1週間 パフォーマンス:
-9.45%
1か月 パフォーマンス:
-10.64%
6か月 パフォーマンス:
-65.80%
1年 パフォーマンス:
-59.40%
1日の値動き範囲:
$29.29
$30.27
1週間の範囲:
$29.08
$34.50
52週間の値動き範囲:
$27.66
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
名前
Vaxcyte Inc
セクター
電話
650-837-0111
住所
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
PCVX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
29.90 | 4.26B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 開始されました | Goldman | Buy |
| 2023-12-07 | 開始されました | Mizuho | Buy |
| 2023-04-18 | 開始されました | TD Cowen | Outperform |
| 2023-01-03 | 繰り返されました | Needham | Buy |
| 2022-12-15 | 開始されました | Guggenheim | Buy |
| 2022-11-17 | 開始されました | BTIG Research | Buy |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-06-24 | 再開されました | Jefferies | Buy |
| 2020-07-07 | 開始されました | BofA Securities | Buy |
| 2020-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 開始されました | Needham | Buy |
すべてを表示
Vaxcyte Inc (PCVX) 最新ニュース
Guggenheim lowers Vaxcyte stock price target to $116 on trial timeline shifts - Investing.com Canada
Vaxcyte’s Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks
Vaxcyte, Inc. shares fall 9.56% intraday after FDA interactions and Phase 3 clinical program finalization. - AInvest
Vaxcyte price target lowered to $50 from $85 at TD Cowen - TipRanks
Vaxcyte’s Strategic Adjustments and Optimized Trials Drive Buy Rating - TipRanks
Vaxcyte Q2 EPS $1.22, beats consensus $1.16; CEO discusses Phase 3 program for VAX-31. - AInvest
Vaxcyte (PCVX) Q2 Loss Widens 11% - AOL.com
Vaxcyte (PCVX) Q2 Loss Widens 11% - The Motley Fool
Promising Prospects for Vaxcyte’s VAX-31: Strong Adult Trial Results and Strategic Advancements in Infant Studies Reinforce Buy Rating - TipRanks
Vaxcyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) - GlobeNewswire
Vaxcyte's VAX-31 Vaccine Gets FDA Green Light for Phase 3 Launch: $2.8B War Chest Powers Clinical Progress - Stock Titan
MACD Signals Flash Warning for Vaxcyte Inc. StockMulti-Bagger Potential Stock Forecast Tools Released - metal.it
What is the dividend policy of Vaxcyte Inc. stockStay ahead with advanced stock screening tools - Jammu Links News
How strong is Vaxcyte Inc. company’s balance sheetUnprecedented profits - Jammu Links News
How does Vaxcyte Inc. compare to its industry peersDiscover stocks with explosive upside potential - Jammu Links News
Is Vaxcyte Inc. stock overvalued or undervaluedAchieve breakthrough performance in the market - Jammu Links News
Is Vaxcyte Inc. a growth stock or a value stockFree Investment Risk Control - Jammu Links News
How does Vaxcyte Inc. generate profit in a changing economyAchieve rapid financial growth with smart picks - Jammu Links News
When is Vaxcyte Inc. stock expected to show significant growthUnlock powerful stock screening tools today - Jammu Links News
Is it the right time to buy Vaxcyte Inc. stockDiscover stocks with explosive growth potential - Jammu Links News
What drives Vaxcyte Inc. stock priceInvest smarter with real-time trading signals - Jammu Links News
What are the latest earnings results for Vaxcyte Inc.Stay ahead with advanced stock screening tools - Jammu Links News
What are analysts’ price targets for Vaxcyte Inc. in the next 12 monthsBuild a diversified portfolio for steady growth - Jammu Links News
Should I hold or sell Vaxcyte Inc. stock in 2025Phenomenal capital appreciation - Jammu Links News
What institutional investors are buying Vaxcyte Inc. stockPowerful profit generation - Jammu Links News
InvestingPro’s Fair Value model predicted Vaxcyte’s 46% decline By Investing.com - Investing.com
Vaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in Infants - Yahoo Finance
What markets is Vaxcyte Inc. expanding into Is FDUS stock a good long term investment optionFree Stock Target Finder That Work - Jammu Links News
11 Best Future Stocks to Buy Now - Insider Monkey
What makes Vaxcyte Inc. stock price move sharplyMarket Entry and Exit Point Tips From Traders - metal.it
What is the risk reward ratio of investing in Vaxcyte Inc. stockInvest smarter with daily stock recommendations - Jammu Links News
What catalysts could drive Vaxcyte Inc. stock higher in 2025Rapid growth trajectories - Jammu Links News
Vaxcyte Inc (PCVX) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
3.39%
大文字化:
|
ボリューム (24 時間):